LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma

American Journal of Clinical Pathology

Volumn 137, Issue 6, 2012, Pages 971-977

  Lin, Chih Kung ^a   Chao, Tai Kuang ^a   Lai, Hung Cheng ^a   Lee, Herng Sheng ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Immunostaining score; LMX1A; Osteopontin

Indexed keywords

LIM HOMEOBOX TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; LIM HOMEODOMAIN PROTEIN; LMX1A PROTEIN, HUMAN; OSTEOPONTIN;

ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CYSTADENOCARCINOMA; DISEASE MARKER; DISEASE SEVERITY; ENDOMETRIOID ADENOCARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARIAN MUCINOUS CYSTADENOCARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; ADENOCARCINOMA; ENDOMETRIOID CARCINOMA; METABOLISM; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; LIM-HOMEODOMAIN PROTEINS; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863753660     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPIX0RUO5PGLXD     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. Cancer J Clin. 2006;56:106-130.
2. Cannistra SA. Cancer of the ovary. N Engl J Med. 1993;329:1550-1559. (Pubitemid 23332443)
3. Menon U. Ovarian cancer: challenges of early detection. Nat Clin Pract Oncol. 2007;4:498-499. (Pubitemid 47351456)
4. Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques. 2001;30:670-675. (Pubitemid 32202873)
5. Schorge JO, Drake RD, Lee H, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res. 2004;10:3474-3478. (Pubitemid 38685455)
6. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008;14:1065-1072. (Pubitemid 351302552)
7. Liu CY, Chao TK, Su PH, et al. Characterization of LMX-1A as a metastasis suppressor in cervical cancer. J Pathol. 2009;219:222-231.
8. Lai HC, Lin YW, Huang TH, et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008;123:161-167. (Pubitemid 351705204)
9. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics. Cancer J Clin. 2001;51:15-36.
10. Partin AW, Shoeniger JS, Mohler LL, et al. Further analysis of cell motility: correlation of motility with metastatic potentials. Proc Natl Acad Sci. 1989;86:1254-1258. (Pubitemid 19061525)
11. Chakraborty G, Jain S, Behera R, et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med. 2006;6:819-830. (Pubitemid 44883934)
12. Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl. 1998;30-31:92-102. (Pubitemid 29028730)
13. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001;1552:61-85. (Pubitemid 34124131)
14. Furger KA, Menon RK, Tuck AB, et al. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med. 2001;1:621-632. (Pubitemid 33772040)
15. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia. 2001;6:419-429.
16. Tuck AB, Elliott BE, Hota C, et al. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem. 2000;78:465-475. (Pubitemid 30491074)
17. Toy H, Yavas O, Eren O, et al. Correlation between osteopontin protein expression and histological grade of astrocytomas. Pathol Oncol Res. 2009;15:203-207.
18. Matsuura M, Suzuki T, Saito T. Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci. 2010;101:1828-1833.
19. Hobert O, Westphal H. Functions of LIM-homeobox genes. Trends Genet. 2000;16:75-83. (Pubitemid 30084720)
20. Dawid IB, Breen JJ, Toyama R. LIM domains: multiple roles as adapters and functional modifiers in protein interactions. Trends Genet. 1998;14:156-162. (Pubitemid 28206396)
21. Chizhikov VV, Lindgren AG, Mishima Y, et al. Lmx1a regulates fates and location of cells originating from the cerebellar rhombic lip and telencephalic cortical hem. Proc Natl Acad Sci U S A. 2010;107:10725-10730.
22. Cai J, Donaldson A, Yang M, et al. The role of Lmx1a in the differentiation of human embryonic stem cells into midbrain dopamine neurons in culture and after transplantation into a Parkinson's disease model. Stem Cells. 2009;27:220-229.